Excessive degradation of adenine nucleotides by up-regulated AMP deaminase underlies afterload-induced diastolic dysfunction in the type 2 diabetic heart

Journal of Molecular and Cellular Cardiology

Volumn 80, Issue , 2015, Pages 136-145

  Kouzu, Hidemichi ^a   Miki, Takayuki ^a   Tanno, Masaya ^a   Kuno, Atsushi ^a   Yano, Toshiyuki ^a   Itoh, Takahito ^a   Sato, Tatsuya ^a   Sunaga, Daisuke ^a   Murase, Hiromichi ^a   Tobisawa, Toshiyuki ^a   Ogasawara, Makoto ^a   Ishikawa, Satoko ^a   Miura, Tetsuji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetes mellitus; Diastolic function; Heart failure; Metabolism

Indexed keywords

ADENINE NUCLEOTIDE; ADENOSINE MONOPHOSPHATE DEAMINASE; CONNECTIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; MYOSIN; PROTEIN C; TROPONIN I; VASODILATOR STIMULATED PHOSPHOPROTEIN; ISOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA PRESSURE; ARTICLE; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; ENERGY METABOLISM; GLYCOLYSIS; HEART AFTERLOAD; HEART CONTRACTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART RATE; METABOLOME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; TACHYCARDIA; ANIMAL; COMPLICATION; DISEASE MODEL; GENE EXPRESSION; GENETICS; HEART FAILURE, DIASTOLIC; HEART FUNCTION TEST; HEART MUSCLE; HEART VENTRICLE FUNCTION; HEMODYNAMICS; METABOLISM; METABOLOMICS; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION;

ADENINE NUCLEOTIDES; AMP DEAMINASE; ANIMALS; CONNECTIN; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HEART FAILURE, DIASTOLIC; HEART FUNCTION TESTS; HEMODYNAMICS; METABOLOME; METABOLOMICS; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHOSPHORYLATION; PROTEIN ISOFORMS; RATS; VENTRICULAR FUNCTION;

EID: 84921644606     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.01.004     Document Type: Article

References (48)

1. Nichols G.A., Gullion C.M., Koro C.E., Ephross S.A., Brown J.B. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004, 27:1879-1884.
2. MacDonald M.R., Petrie M.C., Varyani F., Ostergren J., Michelson E.L., Young J.B., et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008, 29:1377-1385.
3. Gandhi S.K., Powers J.C., Nomeir A.M., Fowle K., Kitzman D.W., Rankin K.M., et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001, 344:17-22.
4. Kim S.A., Shim C.Y., Kim J.M., Lee H.J., Choi D.H., Choi E.Y., et al. Impact of left ventricular longitudinal diastolic functional reserve on clinical outcome in patients with type 2 diabetes mellitus. Heart 2011, 97:1233-1238.
5. Kawaguchi M., Hay I., Fetics B., Kass D.A. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003, 107:714-720.
6. Borlaug B.A., Jaber W.A., Ommen S.R., Lam C.S., Redfield M.M., Nishimura R.A. Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart 2011, 97:964-969.
7. Miki T., Yuda S., Kouzu H., Miura T. Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev 2013, 18:149-166.
8. Hotta H., Miura T., Miki T., Togashi N., Maeda T., Kim S.J., et al. Angiotensin II type 1 receptor-mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts. Circ Res 2010, 106:129-132.
9. Miki T., Miura T., Hotta H., Tanno M., Yano T., Sato T., et al. Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-glycogen synthase kinase-3beta-mediated suppression of mitochondrial permeability transition. Diabetes 2009, 58:2863-2872.
10. Takada A., Miki T., Kuno A., Kouzu H., Sunaga D., Itoh T., et al. Role of ER stress in ventricular contractile dysfunction in type 2 diabetes. PLoS One 2012, 7:e39893.
11. Burkhoff D., Mirsky I., Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 2005, 289:H501-H512.
12. Shapiro B.P., Lam C.S., Patel J.B., Mohammed S.F., Kruger M., Meyer D.M., et al. Acute and chronic ventricular-arterial coupling in systole and diastole: insights from an elderly hypertensive model. Hypertension 2007, 50:503-511.
13. Chatham J.C., Seymour A.M. Cardiac carbohydrate metabolism in Zucker diabetic fatty rats. Cardiovasc Res 2002, 55:104-112.
14. Neagoe C., Opitz C.A., Makarenko I., Linke W.A. Gigantic variety: expression patterns of titin isoforms in striated muscles and consequences for myofibrillar passive stiffness. J Muscle Res Cell Motil 2003, 24:175-189.
15. Falcão-Pires I., Hamdani N., Borbély A., Gavina C., Schalkwijk C.G., van der Velden J., et al. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation 2011, 124:1151-1159.
16. Hamdani N., Franssen C., Lourenço A., Falcão-Pires I., Fontoura D., Leite S., et al. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail 2013, 6:1239-1249.
17. Kötter S., Gout L., Von Frieling-Salewsky M., Müller A.E., Helling S., Marcus K., et al. Differential changes in titin domain phosphorylation increase myofilament stiffness in failing human hearts. Cardiovasc Res 2013, 99:648-656.
18. Heather L.C., Clarke K. Metabolism, hypoxia and the diabetic heart. J Mol Cell Cardiol 2011, 50:598-605.
19. Serpillon S., Floyd B.C., Gupte R.S., George S., Kozicky M., Neito V., et al. Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am J Physiol Heart Circ Physiol 2009, 297:H153-H162.
20. Kato T., Niizuma S., Inuzuka Y., Kawashima T., Okuda J., Tamaki Y., et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 2010, 3:420-430.
21. Taegtmeyer H. On the role of the purine nucleotide cycle in the isolated working rat heart. J Mol Cell Cardiol 1985, 17:1013-1018.
22. Zoref-Shani E., Kessler-Icekson G., Sperling O. Pathways of adenine nucleotide catabolism in primary rat cardiomyocyte cultures. J Mol Cell Cardiol 1988, 20:23-33.
23. Scheuermann-Freestone M., Madsen P.L., Manners D., Blamire A.M., Buckingham R.E., Styles P., et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003, 107:3040-3046.
24. Saks V., Dzeja P., Schlattner U., Vendelin M., Terzic A., Wallimann T. Cardiac system bioenergetics: metabolic basis of the Frank-Starling law. J Physiol 2006, 571:253-273.
25. Dzeja P.P., Vitkevicius K.T., Redfield M.M., Burnett J.C., Terzic A. Adenylate kinase-catalyzed phosphotransfer in the myocardium: increased contribution in heart failure. Circ Res 1999, 84:1137-1143.
26. Ouyang J., Parakhia R.A., Ochs R.S. Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 2011, 286:1-11.
27. Lanaspa M.A., Cicerchi C., Garcia G., Li N., Roncal-Jimenez C.A., Rivard C.J., et al. Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver. PLoS One 2012, 7:e48801.
28. Paolocci N., Tavazzi B., Biondi R., Gluzband Y.A., Amorini A.M., Tocchetti C.G., et al. Metalloproteinase inhibitor counters high-energy phosphate depletion and AMP deaminase activity enhancing ventricular diastolic compliance in subacute heart failure. J Pharmacol Exp Ther 2006, 317:506-513.
29. Cheng J., Morisaki H., Toyama K., Ikawa M., Okabe M., Morisaki T. AMPD3-deficient mice exhibit increased erythrocyte ATP levels but anemia not improved due to PK deficiency. Genes Cells 2012, 17:913-922.
30. Hohl A.M., Hohl C.M. Isolation and regulation of piglet cardiac AMP deaminase. Mol Cell Biochem 1999, 201:151-158.
31. Barsacchi R., Ranieri-Raggi M., Bergamini C., Raggi A. Adenylate metabolism in the heart. Regulatory properties of rabbit cardiac adenylate deaminase. Biochem J 1979, 182:361-366.
32. Geraldes P., King G.L. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010, 106:1319-1331.
33. Podgorska M., Kocbuch K., Grden M., Szutowicz A., Pawelczyk T. Prevalence of unidirectional Na+-dependent adenosine transport and altered potential for adenosine generation in diabetic cardiac myocytes. Basic Res Cardiol 2006, 101:214-222.
34. Cicerchi C., Li N., Kratzer J., Garcia G., Roncal-Jimenez C.A., Tanabe K., et al. Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids. FASEB J 2014, 28:3339-3350.
35. Tanfani F., Kossowska E., Purzycka-Preis J., Zydowo M.M., Wozniak M., Tartaglini E., et al. The interaction of phospholipid bilayers with pig heart AMP deaminase: Fourier-transform infrared spectroscopic and kinetic studies. Biochem J 1993, 291:921-926.
36. Kersten J.R., Toller W.G., Gross E.R., Pagel P.S., Warltier D.C. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 2000, 278:H1218-H1224.
37. Kass D.A., Bronzwaer J.G., Paulus W.J. What mechanisms underlie diastolic dysfunction in heart failure?. Circ Res 2004, 94:1533-1542.
38. Kammermeier H. High energy phosphate of the myocardium: concentration versus free energy change. Basic Res Cardiol 1987, 82:31-36.
39. Momomura S., Ingwall J.S., Parker J.A., Sahagian P., Ferguson J.J., Grossman W. The relationships of high energy phosphates, tissue pH, and regional blood flow to diastolic distensibility in the ischemic dog myocardium. Circ Res 1985, 57:822-835.
40. Bernard M., Neubauer S., Ingwall J.S. On the relations among ATP hydrolysis, cation accumulation and diastolic dysfunction. Diastolic Relaxation of the Heart 1994, 73-78. Kluwer Academic Publishers, Boston, Mass. B.H. Lorell, W. Grossman (Eds.).
41. Tian R., Christe M.E., Spindler M., Hopkins J.C., Halow J.M., Camacho S.A., et al. Role of MgADP in the development of diastolic dysfunction in the intact beating rat heart. J Clin Invest 1997, 99:745-751.
42. Tian R., Nascimben L., Ingwall J.S., Lorell B.H. Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. Circulation 1997, 96:1313-1319.
43. Spindler M., Saupe K.W., Tian R., Ahmed S., Matlib M.A., Ingwall J.S. Altered creatine kinase enzyme kinetics in diabetic cardiomyopathy. A(31)P NMR magnetization transfer study of the intact beating rat heart. J Mol Cell Cardiol 1999, 31:2175-2189.
44. Katz L.A., Swain J.A., Portman M.A., Balaban R.S. Relation between phosphate metabolites and oxygen consumption of heart in vivo. Am J Physiol 1989, 256:H265-H274.
45. Rodríguez-Sinovas A., Sánchez J.A., González-Loyola A., Barba I., Morente M., Aguilar R., et al. Effects of substitution of Cx43 by Cx32 on myocardial energy metabolism, tolerance to ischaemia and preconditioning protection. J Physiol 2010, 588:1139-1151.
46. Shao C.H., Capek H.L., Patel K.P., Wang M., Tang K., DeSouza C., et al. Carbonylation contributes to SERCA2a activity loss and diastolic dysfunction in a rat model of type 1 diabetes. Diabetes 2011, 60:947-959.
47. Krüger M., Babicz K., von Frieling-Salewsky M., Linke W.A. Insulin signaling regulates cardiac titin properties in heart development and diabetic cardiomyopathy. J Mol Cell Cardiol 2010, 48:910-916.
48. Yagi K., Kim S., Wanibuchi H., Yamashita T., Yamamura Y., Iwao H. Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima fatty rats. Hypertension 1997, 29:728-735.